FDA Approves Enasidenib for Adults with Relapsed or Refractory AML with an IDH2 Mutation

Jul 31

2017

The U.S. Food and Drug Administration granted regular approval to enasidenib (IDHIFA, Celgene Corp.) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Citations

APA

American Society of Hematology. (2017).
FDA Approves Enasidenib for Adults with Relapsed or Refractory AML with an IDH2 Mutation.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-enasidenib-for-adults-with-relapsed-or-refractory-aml-with-an-idh2-mutation.

Chicago

American Society of Hematology.
"FDA Approves Enasidenib for Adults with Relapsed or Refractory AML with an IDH2 Mutation." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-enasidenib-for-adults-with-relapsed-or-refractory-aml-with-an-idh2-mutation
(label-accessed December 12, 2024).

MLA

"American Society of Hematology."
FDA Approves Enasidenib for Adults with Relapsed or Refractory AML with an IDH2 Mutation, 12 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-enasidenib-for-adults-with-relapsed-or-refractory-aml-with-an-idh2-mutation.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Related Content

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission